V590

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
V590
DrugBank Accession Number
DB16437
Background

The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®1,2,3. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose4. Other features of this vaccine include potential activity with oral administration via a swish-and-swallow protocol4. Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786).

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Recombinant
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Wolf J, Bruno S, Eichberg M, Jannat R, Rudo S, VanRheenen S, Coller BA: Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. NPJ Vaccines. 2020 Jun 15;5:51. doi: 10.1038/s41541-020-0204-7. eCollection 2020. [Article]
  2. Genetic Engineering & Biotechnology News (GEN): Merck & Co. and IAVI – V590 [Link]
  3. MERCK: IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2 [Link]
  4. The Motley Fool: This Late-to-the-Party Coronavirus Vaccine Maker Could Be the Biggest Winner Over the Long Run [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedPreventionCoronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on January 15, 2021 18:44 / Updated on January 16, 2021 21:46